Optimization of Aminoimidazole Derivatives as Src Family Kinase Inhibitors
Protein kinases have emerged as crucial targets for cancer therapy over the last decades. Since 2001, 40 and 39 kinase inhibitors have been approved by FDA and EMA, respectively, and the majority are antineoplastic drugs. Morevoer, many candidates are currently in clinical trials. We previously reported a small library of 4-aminoimidazole and 2-aminothiazole derivatives active as Src family kinase (SFK) inhibitors. Starting from these results, we decided to perform an optimization study applying a mix and match strategy to identify a more potent generation of 4-aminoimidazoles. Firstly, a computational study has been performed, then compounds showing the best predicted docking scores were synthesized and screened in a cell-free assay for their SFK inhibitory activity. All the new chemical entities showed IC50s in the nanomolar range, with 2⁻130 fold increased activities compared to the previously reported inhibitors. Finally, the most active compounds have been tested on three cancer cell lines characterized by Src hyperactivation. Compounds 4k and 4l showed an interesting antiproliferative activity on SH-SY5Y neuroblastoma (NB) cell line. In this assay, the compounds resulted more potent than dasatinib, a tyrosine kinase inhibitor approved for the treatment of leukemias and in clinical trials for NB.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2018 |
|---|---|
| Erschienen: |
2018 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:23 |
|---|---|
| Enthalten in: |
Molecules (Basel, Switzerland) - 23(2018), 9 vom: 17. Sept. |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Francini, Cinzia Maria [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 11.12.2018 Date Revised 11.12.2018 published: Electronic Citation Status MEDLINE |
|---|
| doi: |
10.3390/molecules23092369 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM288643569 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM288643569 | ||
| 003 | DE-627 | ||
| 005 | 20231225060801.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2018 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.3390/molecules23092369 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n0962.xml |
| 035 | |a (DE-627)NLM288643569 | ||
| 035 | |a (NLM)30227617 | ||
| 035 | |a (PII)E2369 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Francini, Cinzia Maria |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Optimization of Aminoimidazole Derivatives as Src Family Kinase Inhibitors |
| 264 | 1 | |c 2018 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 11.12.2018 | ||
| 500 | |a Date Revised 11.12.2018 | ||
| 500 | |a published: Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Protein kinases have emerged as crucial targets for cancer therapy over the last decades. Since 2001, 40 and 39 kinase inhibitors have been approved by FDA and EMA, respectively, and the majority are antineoplastic drugs. Morevoer, many candidates are currently in clinical trials. We previously reported a small library of 4-aminoimidazole and 2-aminothiazole derivatives active as Src family kinase (SFK) inhibitors. Starting from these results, we decided to perform an optimization study applying a mix and match strategy to identify a more potent generation of 4-aminoimidazoles. Firstly, a computational study has been performed, then compounds showing the best predicted docking scores were synthesized and screened in a cell-free assay for their SFK inhibitory activity. All the new chemical entities showed IC50s in the nanomolar range, with 2⁻130 fold increased activities compared to the previously reported inhibitors. Finally, the most active compounds have been tested on three cancer cell lines characterized by Src hyperactivation. Compounds 4k and 4l showed an interesting antiproliferative activity on SH-SY5Y neuroblastoma (NB) cell line. In this assay, the compounds resulted more potent than dasatinib, a tyrosine kinase inhibitor approved for the treatment of leukemias and in clinical trials for NB | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a SFK inhibitors | |
| 650 | 4 | |a aminoimidazole | |
| 650 | 4 | |a anticancer | |
| 650 | 4 | |a neuroblastoma | |
| 650 | 4 | |a tyrosine kinases | |
| 650 | 7 | |a Imidazoles |2 NLM | |
| 650 | 7 | |a Protein Kinase Inhibitors |2 NLM | |
| 650 | 7 | |a 4-aminoimidazole |2 NLM | |
| 650 | 7 | |a 4919-03-3 |2 NLM | |
| 650 | 7 | |a Adenosine Triphosphate |2 NLM | |
| 650 | 7 | |a 8L70Q75FXE |2 NLM | |
| 650 | 7 | |a src-Family Kinases |2 NLM | |
| 650 | 7 | |a EC 2.7.10.2 |2 NLM | |
| 700 | 1 | |a Musumeci, Francesca |e verfasserin |4 aut | |
| 700 | 1 | |a Fallacara, Anna Lucia |e verfasserin |4 aut | |
| 700 | 1 | |a Botta, Lorenzo |e verfasserin |4 aut | |
| 700 | 1 | |a Molinari, Alessio |e verfasserin |4 aut | |
| 700 | 1 | |a Artusi, Roberto |e verfasserin |4 aut | |
| 700 | 1 | |a Mennuni, Laura |e verfasserin |4 aut | |
| 700 | 1 | |a Angelucci, Adriano |e verfasserin |4 aut | |
| 700 | 1 | |a Schenone, Silvia |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Molecules (Basel, Switzerland) |d 2004 |g 23(2018), 9 vom: 17. Sept. |w (DE-627)NLM172073448 |x 1420-3049 |7 nnns |
| 773 | 1 | 8 | |g volume:23 |g year:2018 |g number:9 |g day:17 |g month:09 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.3390/molecules23092369 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 23 |j 2018 |e 9 |b 17 |c 09 | ||